Product Overview
CJC-1295 + Ipamorelin is a combined peptide formulation supplied for use in controlled laboratory and research environments.
This blend combines two synthetic peptide compounds commonly investigated in preclinical research models relating to growth hormone signalling pathways, receptor interaction dynamics, peptide stability, and endocrine-associated biological processes.
CJC-1295 is a modified growth hormone releasing hormone (GHRH) analogue, while Ipamorelin is a selective growth hormone secretagogue frequently studied for its receptor-targeted signalling behaviour under controlled experimental conditions.
The combined formulation is commonly utilised in laboratory settings examining synergistic peptide interaction, signalling activity, and regulated biological response mechanisms within controlled research models.
Supplied in lyophilised form, each vial is prepared to support precision handling, stability, and reproducibility within laboratory environments.
Verification Standard
Every batch of CJC-1295 + Ipamorelin supplied by Peptology Labs undergoes a controlled, batch-specific verification process:
- High-Performance Liquid Chromatography (HPLC) purity analysis
- Mass spectrometry (LC-MS) identity confirmation
- Independently tested by a third-party analytical laboratory
- Additional verification through internationally recognised analytical partners such as Janoshik Analytical
Batch-specific Certificates of Analysis (COAs) are provided for full transparency and traceability.
Product Specification
- Quantity: 10mg blend per vial
- Form: Lyophilised powder
- Purity: ≥99% (HPLC)
- Verification: Independently tested (batch specific)
- Storage: Store refrigerated in a dry environment
- Intended Use: Research use only. Not for human or veterinary use.
